Practical Considerations for the Pharmacotherapy of Pulmonary Arterial Hypertension (original) (raw)

Abstract

Pulmonary arterial hypertension is a devastating disease. Before the 1990s, when pharmacologic treatment was finally approved, only supportive therapy was available, consisting of anticoagulation, digoxin, diuretics, and supplemental oxygen. Calcium channel blocker therapy was also an option, but only a small percentage of patients respond to it. However, starting with epoprostenol in 1996, the number of drugs approved to treat pulmonary arterial hypertension increased. Three distinct classes of drugs were developed based on the pathophysiology of the disease: the prostanoids, endothelin-1 receptor antagonists, and phosphodiesterase type 5 inhibitors. The prostanoids are administered either parenterally or by inhalation to replace the lack of prostacyclin within the pulmonary arterial vasculature. The endothelin-1 receptor antagonists were the first class of oral drugs to be developed, but drug interactions and adverse effects are prominent with this class. The phosphodiesterase type 5 inhibitors increase the second messenger cyclic guanosine monophosphate (GMP) that is induced by nitric oxide stimulation. All of the drugs within these three classes are distinct in and of themselves, and their clinical use requires in-depth knowledge of pulmonary arterial hypertension and its pathophysiology. Because these drugs have different mechanisms of action, combination therapy has shown promise in patients with severe disease, although data are still lacking. This article should serve as a practical guide for clinicians who encounter patients with pulmonary arterial hypertension and the drugs used for the treatment of this devastating disease.

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (68)

  1. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classifications of pulmonary hypertension. J Am Coll Cardiol 2009;54(1 suppl):S43-54.
  2. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hyperten- sion of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the Interna- tional Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009;30:2493-537.
  3. Rich S, Dantzker DR, Ayers SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987;107:216-23.
  4. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991;115:343-9.
  5. Badesch DB, Champion HC, Sanchez MAG, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54:S55-66.
  6. McLaughlin VV, McGoon MD. Pulmonary arterial hyperten- sion. Circulation 2006;114:1417-31.
  7. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA Guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American Col- lege of Cardiology/American Heart Association task force on practice guidelines (committee to revise the 1995 guidelines for the evaluation and management of heart failure): developed in collaboration with the International Society for Heart and Lung Transplantation. Endorsed by the Heart Failure Society of America. Circulation 2001;104:2996-3007.
  8. Rich S, ed. Primary pulmonary hypertension: executive sum- mary from the world symposium on primary pulmonary hypertension. 1998 Sept 6-10; Evian, France: World Health Organization, 1998.
  9. Rich S, McLaughlin VV. Braunwald's heart disease: a textbook of heart disease. In: Bonow RO, Mann DL, Zipes DP, Libbey P, eds. Pulmonary hypertension, 8th ed. Philadelphia, PA: Saun- ders, 2008:1883-914.
  10. Tuder RM, Marecki JC, Richter A, Fijalkowska I, Flores S. Pathology of pulmonary hypertension. Clin Chest Med 2007;28:23-42.
  11. Yuan JX, Rubin LJ. Pathogenesis of pulmonary arterial hyper- tension: the need for multiple hits [editorial]. Circulation 2005;111:534-8.
  12. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004;351:1655-65.
  13. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology foundation task force on expert consensus documents and the American Heart Association: developed in collaboration with the Ameri- can College of Chest Physicians, American Thoracic Society Inc., and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009;53:1573-619.
  14. Alam S, Palevsky HI. Standard therapies for pulmonary arte- rial hypertension. Clin Chest Med 2007;28:91-115.
  15. Rich S, Kaufmann E, Levy PS. The effect of high doses of cal- cium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327:76-81.
  16. Rich S, Brundage BH. High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regres- sion of right ventricular hypertrophy. Circulation 1987;76: 135-41.
  17. Partanen J, Nieminen MS, Luomanmaki K. Death in a patient with primary pulmonary hypertension after 20 mg of nifedi- pine (letter). N Eng J Med 1993;329:812-13.
  18. Aromatorio GJ, Uretsky BF, Reddy PS. Hypotension and sinus arrest with nifedipine in pulmonary hypertension (letter). Chest 1985;87:265-7.
  19. Farber HW, Karlinsky JB, Faling LJ. Fatal outcome following nifedipine for pulmonary hypertension (letter). Chest 1983;83:708-9.
  20. Badesch DB, Abman SH, Ahearn GS, et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126(1 suppl):35S-62S.
  21. Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaugh- lin VV. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 2007;131:1917-28.
  22. Woodmansey PA, O'Toole L, Channer KS, et al. Acute pul- monary vasodilatory properties of amlodipine in humans with pulmonary hypertension. Heart 1996;75:171-3.
  23. Rubin LJ, Nicod P, Hillis LD, et al. Treatment of primary pul- monary hypertension with nifedipine. Ann Intern Med 1983;99:433-8.
  24. Sitbon O, Humbert M, Jais X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005;111:3105-11.
  25. Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prosta- cyclin (epoprostenol). Ann Intern Med 1990;112:485-91.
  26. Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994;121:409-15.
  27. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continu- ous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The primary pulmonary hypertension study group. N Eng J Med 1996;334:296-302.
  28. Miyamoto S, Nagaya N, Satoh T, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopul- monary exercise testing. Am J Respir Crit Care Med 2000;1(2 Pt 1):487-92.
  29. GlaxoSmithKline. Flolan (epoprostenol) package insert. Research Triangle Park, NC: GlaxoSmithKline, 2008.
  30. Actelion Pharmaceuticals US Inc. Veletri (epoprostenol). South San Francisco, CA: Actelion Pharmaceuticals US Inc., 2010.
  31. Thomson Reuters Healthcare Inc. Redbook TM for Windows ® [intranet database]. Version 61127. Greenwood Village, CO: Thomson Reuters Healthcare Inc, 2010.
  32. McLaughlin VV, Gaine SP, Barst RJ, et al. Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol 2003;41:293-9.
  33. Tapson VF, Gomberg Maitland M, McLaughlin VV, et al. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. Chest 2006;129:683-8.
  34. Gomberg Maitland M, Tapson VF, Benza RL, et al. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. Am J Respir Crit Care Med 2005;172:1586-9.
  35. United Therapeutics Corp. Remodulin (treprostinil) package insert. Research Triangle Park, NC: United Therapeutics Corp, 2010.
  36. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutane- ous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:800-4.
  37. Barst RJ, Galie N, Naeije R, et al. Long-term outcome in pul- monary arterial hypertension patients treated with subcutane- ous treprostinil. Eur Respir J 2006;28:1195-203.
  38. Actelion Pharmaceuticals US Inc. Ventavis (iloprost) package insert. South San Francisco, CA: Actelion Pharmaceuticals US Inc, 2011.
  39. Machherndl S, Kneussl M, Baumgartner H, et al. Long-term treatment of pulmonary hypertension with aerosolized ilo- prost. Eur Respir J 2001;17:8-13.
  40. Olschewski H, Ghofrani HA, Walmrath D, et al. Inhaled pros- tacyclin and iloprost in severe pulmonary hypertension sec- ondary to lung fibrosis. Am J Respir Crit Care Med 1999;160:600-7.
  41. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Eng J Med 2002;347:322-9.
  42. Denyer J, Dyche T. The Adaptive aerosol delivery (AAD) tech- nology: past, present and future. J Aerosol Med Pulm Drug Deliv 2010;23(suppl 1):S1-10.
  43. Dhand R. Intelligent nebulizers in the age of the internet: the I-neb adaptive aerosol delivery (AAD) system (editorial). J Aerosol Med Pulm Drug Deliv 2010;23(suppl 1):iii-v.
  44. Van Dyke R, Nikander K. Decreased treatment times with aerosolized iloprost following increase in power levels for the I-neb adaptive aerosol delivery (AAD) system. Paper presented at the Drug Delivery to the Lungs conference; 2008 Dec 10- 12; Edinburgh, UK.
  45. United Therapeutics Corp. Tyvaso (treprostinil) package insert. Research Triangle Park, NC: United Therapeutics Corp, 2011.
  46. Voswinckel R, Enke B, Reichenberger F, et al. Favorable effects of inhaled treprostinil in severe pulmonary hyperten- sion: results from randomized controlled pilot studies. J Am Coll Cardiol 2006;48:1672-81.
  47. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pul- monary arterial hypertension. N Engl J Med 2002;346:896-903.
  48. Galie N, Manes A, Branzi A. The endothelin system in pulmo- nary arterial hypertension. Cardiovasc Res 2004;61:227-37.
  49. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001;358:1119-23.
  50. McLaughlin VV, Sitbon O, Badesch DB, et al. Survival with first-line bosentan in patients with primary pulmonary hyper- tension. Eur Respir J 2005;25:244-9.
  51. Sitbon O, McLaughlin VV, Badesch DB, et al. Survival in patients with class III idiopathic pulmonary arterial hyperten- sion treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoproste- nol. Thorax 2005;60:1025-30.
  52. Actelion Pharmaceuticals UC Inc. Tracleer (bosentan) pack- age insert. South San Francisco, CA: Actelion Pharmaceuticals UC Inc, 2009.
  53. Galie N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008;117:3010-19.
  54. Galie N, Badesch DB, Oudiz R, et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005;46:529-35.
  55. Gilead Sciences Inc. Letairis (ambrisentan) package insert. Foster City, CA: Gilead Sciences Inc, 2011.
  56. McGoon MD, Frost AE, Oudiz RJ, et al. Ambrisentan therapy in patients with pulmonary arterial hypertension who discon- tinued bosentan or sitaxsentan due to liver function test abnormalities. Chest 2009;135:122-9.
  57. Archer SL, Michelakis ED. Phosphodiesterase type 5 inhibi- tors for pulmonary arterial hypertension. N Engl J Med 2009;361:1864-71.
  58. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148-57.
  59. Badesch DB, Hill NS, Burgess G, et al. Sildenafil for pulmo- nary arterial hypertension associated with connective tissue disease. J Rheumatol 2007;34:2417-22.
  60. Pfizer Inc. Revatio (sildenafil) package insert. New York, NY; 2009.
  61. Galie N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009;119:2894-903.
  62. Eli Lilly anc Company. Adcirca (tadalafil) package insert. Indianapolis, IN: Eli Lilly and Company, 2011.
  63. Humbert M, Barst RJ, Robbins IM, et al. Combination of bos- entan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004;24:353-9.
  64. Simonneau G, Rubin LJ, Galie N, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008;149:521-30.
  65. McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006;174:1257-63.
  66. McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol 2010;55:1915-22.
  67. Barst RJ, Oudiz RJ, Beardsworth A, et al. Tadalafil monother- apy and as add-on to background bosentan in patients with pulmonary arterial hypertension. J Heart Lung Transplant 2011;30:632-43.
  68. Barst RJ, Gibbs JS, Ghofrani HA, et al. Updated evidence- based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2009;1(suppl):S78-84.